Zhi Tong Cai Jing·2026-02-10 06:33Core Viewpoint - The stock price of Tigermed (300347)(03347) has shown a significant rebound after a period of decline, primarily driven by the company's earnings forecast for 2025, which has garnered market recognition for its investment-driven research strategy [1][2]. Group 1: Stock Performance - Tigermed's stock price rebounded from a low of 36.08 HKD on November 21 last year to a peak of 54.85 HKD on January 15, marking a maximum increase of 52.02% [1]. - Following a technical decline, the stock price fell below 50 HKD on January 28 but rebounded sharply on January 29 and 30, indicating a stabilization in its price trend [1]. - After the earnings forecast was released, the stock price opened higher and reached 56.25 HKD, with a trading volume of 704.77 million shares, reflecting strong buying interest from investors [3]. Group 2: Earnings Forecast - Tigermed's earnings forecast for 2025 indicates expected revenue between 6.66 billion to 7.68 billion CNY, representing a year-on-year growth of 1% to 16% [2]. - The net profit attributable to shareholders is projected to be between 830 million to 1.23 billion CNY, showing a significant increase of 105% to 204% year-on-year, primarily due to non-recurring gains [2]. - Non-recurring gains are expected to be between 500 million to 740 million CNY, contributing to the net profit increase, which is largely driven by investment income rather than core clinical CRO business [2]. Group 3: Market Sentiment and Analyst Ratings - Following the earnings announcement, Goldman Sachs adjusted its profit forecasts for Tigermed for 2025 to 2027, with target prices for H-shares and A-shares slightly increased, maintaining a "buy" rating [3]. - UBS also issued a "buy" rating with a target price of 57.1 HKD, focusing on the recovery signals in new order pricing for 2026 [3]. - The shift in trading strategy by Hong Kong Stock Connect funds towards "right-side trading" was noted, particularly after the earnings forecast was disclosed [5][7]. Group 4: Industry Trends - The domestic healthcare financing market has shown signs of recovery, with a 22% year-on-year increase in financing amounts in the first three quarters of 2025, indicating a shift towards more substantial clinical investments [10]. - The approval rates for innovative drug IND applications have improved, with a 96.5% approval rate for Class 1 innovative drugs, suggesting a more favorable regulatory environment [10][11]. - The demand for clinical CRO services is expected to rise as companies increase their clinical trial investments, benefiting leading firms in the sector like Tigermed [11].